Medical Care
Global Indolent Lymphoma Treatment Market Research Report 2025
- Mar 11, 25
- ID: 9238
- Pages: 83
- Figures: 87
- Views: 25
The global market for Indolent Lymphoma Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Indolent Lymphoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Lymphoma Treatment.
The Indolent Lymphoma Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Indolent Lymphoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Indolent Lymphoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Segment by Type
BI-836826
ALT-803
BMS-986016
CC-122
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Indolent Lymphoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Indolent Lymphoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Lymphoma Treatment.
The Indolent Lymphoma Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Indolent Lymphoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Indolent Lymphoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Segment by Type
BI-836826
ALT-803
BMS-986016
CC-122
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Indolent Lymphoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 BI-836826
1.2.3 ALT-803
1.2.4 BMS-986016
1.2.5 CC-122
1.2.6 Others
1.3 Market by Application
1.3.1 Global Indolent Lymphoma Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Indolent Lymphoma Treatment Market Perspective (2020-2031)
2.2 Global Indolent Lymphoma Treatment Growth Trends by Region
2.2.1 Global Indolent Lymphoma Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Indolent Lymphoma Treatment Historic Market Size by Region (2020-2025)
2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Region (2026-2031)
2.3 Indolent Lymphoma Treatment Market Dynamics
2.3.1 Indolent Lymphoma Treatment Industry Trends
2.3.2 Indolent Lymphoma Treatment Market Drivers
2.3.3 Indolent Lymphoma Treatment Market Challenges
2.3.4 Indolent Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Indolent Lymphoma Treatment Players by Revenue
3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2020-2025)
3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Indolent Lymphoma Treatment Revenue
3.4 Global Indolent Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2024
3.5 Global Key Players of Indolent Lymphoma Treatment Head office and Area Served
3.6 Global Key Players of Indolent Lymphoma Treatment, Product and Application
3.7 Global Key Players of Indolent Lymphoma Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Indolent Lymphoma Treatment Breakdown Data by Type
4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2020-2025)
4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2026-2031)
5 Indolent Lymphoma Treatment Breakdown Data by Application
5.1 Global Indolent Lymphoma Treatment Historic Market Size by Application (2020-2025)
5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Indolent Lymphoma Treatment Market Size (2020-2031)
6.2 North America Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Indolent Lymphoma Treatment Market Size by Country (2020-2025)
6.4 North America Indolent Lymphoma Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Indolent Lymphoma Treatment Market Size (2020-2031)
7.2 Europe Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Indolent Lymphoma Treatment Market Size by Country (2020-2025)
7.4 Europe Indolent Lymphoma Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Indolent Lymphoma Treatment Market Size (2020-2031)
8.2 Asia-Pacific Indolent Lymphoma Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Indolent Lymphoma Treatment Market Size (2020-2031)
9.2 Latin America Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Indolent Lymphoma Treatment Market Size by Country (2020-2025)
9.4 Latin America Indolent Lymphoma Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Indolent Lymphoma Treatment Market Size (2020-2031)
10.2 Middle East & Africa Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altor BioScience Corporation
11.1.1 Altor BioScience Corporation Company Details
11.1.2 Altor BioScience Corporation Business Overview
11.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
11.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.1.5 Altor BioScience Corporation Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Details
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
11.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.2.5 Amgen Inc. Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Indolent Lymphoma Treatment Introduction
11.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.4.5 Bayer AG Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Details
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Details
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction
11.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.7.5 Celgene Corporation Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Details
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Gilead Sciences, Inc.
11.10.1 Gilead Sciences, Inc. Company Details
11.10.2 Gilead Sciences, Inc. Business Overview
11.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
11.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.10.5 Gilead Sciences, Inc. Recent Development
11.11 Incyte Corporation
11.11.1 Incyte Corporation Company Details
11.11.2 Incyte Corporation Business Overview
11.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
11.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.11.5 Incyte Corporation Recent Development
11.12 Infinity Pharmaceuticals, Inc.
11.12.1 Infinity Pharmaceuticals, Inc. Company Details
11.12.2 Infinity Pharmaceuticals, Inc. Business Overview
11.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
11.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.12.5 Infinity Pharmaceuticals, Inc. Recent Development
11.13 Juno Therapeutics Inc.
11.13.1 Juno Therapeutics Inc. Company Details
11.13.2 Juno Therapeutics Inc. Business Overview
11.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
11.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.13.5 Juno Therapeutics Inc. Recent Development
11.14 MedImmune, LLC
11.14.1 MedImmune, LLC Company Details
11.14.2 MedImmune, LLC Business Overview
11.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
11.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.14.5 MedImmune, LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 BI-836826
1.2.3 ALT-803
1.2.4 BMS-986016
1.2.5 CC-122
1.2.6 Others
1.3 Market by Application
1.3.1 Global Indolent Lymphoma Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Indolent Lymphoma Treatment Market Perspective (2020-2031)
2.2 Global Indolent Lymphoma Treatment Growth Trends by Region
2.2.1 Global Indolent Lymphoma Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Indolent Lymphoma Treatment Historic Market Size by Region (2020-2025)
2.2.3 Indolent Lymphoma Treatment Forecasted Market Size by Region (2026-2031)
2.3 Indolent Lymphoma Treatment Market Dynamics
2.3.1 Indolent Lymphoma Treatment Industry Trends
2.3.2 Indolent Lymphoma Treatment Market Drivers
2.3.3 Indolent Lymphoma Treatment Market Challenges
2.3.4 Indolent Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Indolent Lymphoma Treatment Players by Revenue
3.1.1 Global Top Indolent Lymphoma Treatment Players by Revenue (2020-2025)
3.1.2 Global Indolent Lymphoma Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Indolent Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Indolent Lymphoma Treatment Revenue
3.4 Global Indolent Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Indolent Lymphoma Treatment Revenue in 2024
3.5 Global Key Players of Indolent Lymphoma Treatment Head office and Area Served
3.6 Global Key Players of Indolent Lymphoma Treatment, Product and Application
3.7 Global Key Players of Indolent Lymphoma Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Indolent Lymphoma Treatment Breakdown Data by Type
4.1 Global Indolent Lymphoma Treatment Historic Market Size by Type (2020-2025)
4.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2026-2031)
5 Indolent Lymphoma Treatment Breakdown Data by Application
5.1 Global Indolent Lymphoma Treatment Historic Market Size by Application (2020-2025)
5.2 Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Indolent Lymphoma Treatment Market Size (2020-2031)
6.2 North America Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Indolent Lymphoma Treatment Market Size by Country (2020-2025)
6.4 North America Indolent Lymphoma Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Indolent Lymphoma Treatment Market Size (2020-2031)
7.2 Europe Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Indolent Lymphoma Treatment Market Size by Country (2020-2025)
7.4 Europe Indolent Lymphoma Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Indolent Lymphoma Treatment Market Size (2020-2031)
8.2 Asia-Pacific Indolent Lymphoma Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Indolent Lymphoma Treatment Market Size (2020-2031)
9.2 Latin America Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Indolent Lymphoma Treatment Market Size by Country (2020-2025)
9.4 Latin America Indolent Lymphoma Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Indolent Lymphoma Treatment Market Size (2020-2031)
10.2 Middle East & Africa Indolent Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altor BioScience Corporation
11.1.1 Altor BioScience Corporation Company Details
11.1.2 Altor BioScience Corporation Business Overview
11.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Introduction
11.1.4 Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.1.5 Altor BioScience Corporation Recent Development
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Details
11.2.2 Amgen Inc. Business Overview
11.2.3 Amgen Inc. Indolent Lymphoma Treatment Introduction
11.2.4 Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.2.5 Amgen Inc. Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Indolent Lymphoma Treatment Introduction
11.4.4 Bayer AG Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.4.5 Bayer AG Recent Development
11.5 Boehringer Ingelheim GmbH
11.5.1 Boehringer Ingelheim GmbH Company Details
11.5.2 Boehringer Ingelheim GmbH Business Overview
11.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Introduction
11.5.4 Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.5.5 Boehringer Ingelheim GmbH Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Details
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Details
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Indolent Lymphoma Treatment Introduction
11.7.4 Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.7.5 Celgene Corporation Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 F. Hoffmann-La Roche Ltd. Company Details
11.9.2 F. Hoffmann-La Roche Ltd. Business Overview
11.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Introduction
11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
11.10 Gilead Sciences, Inc.
11.10.1 Gilead Sciences, Inc. Company Details
11.10.2 Gilead Sciences, Inc. Business Overview
11.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Introduction
11.10.4 Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.10.5 Gilead Sciences, Inc. Recent Development
11.11 Incyte Corporation
11.11.1 Incyte Corporation Company Details
11.11.2 Incyte Corporation Business Overview
11.11.3 Incyte Corporation Indolent Lymphoma Treatment Introduction
11.11.4 Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.11.5 Incyte Corporation Recent Development
11.12 Infinity Pharmaceuticals, Inc.
11.12.1 Infinity Pharmaceuticals, Inc. Company Details
11.12.2 Infinity Pharmaceuticals, Inc. Business Overview
11.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Introduction
11.12.4 Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.12.5 Infinity Pharmaceuticals, Inc. Recent Development
11.13 Juno Therapeutics Inc.
11.13.1 Juno Therapeutics Inc. Company Details
11.13.2 Juno Therapeutics Inc. Business Overview
11.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Introduction
11.13.4 Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.13.5 Juno Therapeutics Inc. Recent Development
11.14 MedImmune, LLC
11.14.1 MedImmune, LLC Company Details
11.14.2 MedImmune, LLC Business Overview
11.14.3 MedImmune, LLC Indolent Lymphoma Treatment Introduction
11.14.4 MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2020-2025)
11.14.5 MedImmune, LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Indolent Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of BI-836826
Table 3. Key Players of ALT-803
Table 4. Key Players of BMS-986016
Table 5. Key Players of CC-122
Table 6. Key Players of Others
Table 7. Global Indolent Lymphoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Indolent Lymphoma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Indolent Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Indolent Lymphoma Treatment Market Share by Region (2020-2025)
Table 11. Global Indolent Lymphoma Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Indolent Lymphoma Treatment Market Share by Region (2026-2031)
Table 13. Indolent Lymphoma Treatment Market Trends
Table 14. Indolent Lymphoma Treatment Market Drivers
Table 15. Indolent Lymphoma Treatment Market Challenges
Table 16. Indolent Lymphoma Treatment Market Restraints
Table 17. Global Indolent Lymphoma Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Indolent Lymphoma Treatment Market Share by Players (2020-2025)
Table 19. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2024)
Table 20. Ranking of Global Top Indolent Lymphoma Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Indolent Lymphoma Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Indolent Lymphoma Treatment, Headquarters and Area Served
Table 23. Global Key Players of Indolent Lymphoma Treatment, Product and Application
Table 24. Global Key Players of Indolent Lymphoma Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Indolent Lymphoma Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Indolent Lymphoma Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Indolent Lymphoma Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Altor BioScience Corporation Company Details
Table 50. Altor BioScience Corporation Business Overview
Table 51. Altor BioScience Corporation Indolent Lymphoma Treatment Product
Table 52. Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 53. Altor BioScience Corporation Recent Development
Table 54. Amgen Inc. Company Details
Table 55. Amgen Inc. Business Overview
Table 56. Amgen Inc. Indolent Lymphoma Treatment Product
Table 57. Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 58. Amgen Inc. Recent Development
Table 59. Astellas Pharma Inc. Company Details
Table 60. Astellas Pharma Inc. Business Overview
Table 61. Astellas Pharma Inc. Indolent Lymphoma Treatment Product
Table 62. Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 63. Astellas Pharma Inc. Recent Development
Table 64. Bayer AG Company Details
Table 65. Bayer AG Business Overview
Table 66. Bayer AG Indolent Lymphoma Treatment Product
Table 67. Bayer AG Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 68. Bayer AG Recent Development
Table 69. Boehringer Ingelheim GmbH Company Details
Table 70. Boehringer Ingelheim GmbH Business Overview
Table 71. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product
Table 72. Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 73. Boehringer Ingelheim GmbH Recent Development
Table 74. Bristol-Myers Squibb Company Company Details
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product
Table 77. Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Celgene Corporation Company Details
Table 80. Celgene Corporation Business Overview
Table 81. Celgene Corporation Indolent Lymphoma Treatment Product
Table 82. Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 83. Celgene Corporation Recent Development
Table 84. Eli Lilly and Company Company Details
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Indolent Lymphoma Treatment Product
Table 87. Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 88. Eli Lilly and Company Recent Development
Table 89. F. Hoffmann-La Roche Ltd. Company Details
Table 90. F. Hoffmann-La Roche Ltd. Business Overview
Table 91. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product
Table 92. F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 93. F. Hoffmann-La Roche Ltd. Recent Development
Table 94. Gilead Sciences, Inc. Company Details
Table 95. Gilead Sciences, Inc. Business Overview
Table 96. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product
Table 97. Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 98. Gilead Sciences, Inc. Recent Development
Table 99. Incyte Corporation Company Details
Table 100. Incyte Corporation Business Overview
Table 101. Incyte Corporation Indolent Lymphoma Treatment Product
Table 102. Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 103. Incyte Corporation Recent Development
Table 104. Infinity Pharmaceuticals, Inc. Company Details
Table 105. Infinity Pharmaceuticals, Inc. Business Overview
Table 106. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product
Table 107. Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 108. Infinity Pharmaceuticals, Inc. Recent Development
Table 109. Juno Therapeutics Inc. Company Details
Table 110. Juno Therapeutics Inc. Business Overview
Table 111. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product
Table 112. Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 113. Juno Therapeutics Inc. Recent Development
Table 114. MedImmune, LLC Company Details
Table 115. MedImmune, LLC Business Overview
Table 116. MedImmune, LLC Indolent Lymphoma Treatment Product
Table 117. MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 118. MedImmune, LLC Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
Table 122. Authors List of This Report
List of Figures
Figure 1. Indolent Lymphoma Treatment Picture
Figure 2. Global Indolent Lymphoma Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Indolent Lymphoma Treatment Market Share by Type: 2024 VS 2031
Figure 4. BI-836826 Features
Figure 5. ALT-803 Features
Figure 6. BMS-986016 Features
Figure 7. CC-122 Features
Figure 8. Others Features
Figure 9. Global Indolent Lymphoma Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Indolent Lymphoma Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Indolent Lymphoma Treatment Report Years Considered
Figure 15. Global Indolent Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Indolent Lymphoma Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Indolent Lymphoma Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Indolent Lymphoma Treatment Market Share by Players in 2024
Figure 19. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2024
Figure 21. North America Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 23. United States Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 27. Germany Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Indolent Lymphoma Treatment Market Share by Region (2020-2031)
Figure 35. China Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Altor BioScience Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 51. Amgen Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 52. Astellas Pharma Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 53. Bayer AG Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 54. Boehringer Ingelheim GmbH Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 55. Bristol-Myers Squibb Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 56. Celgene Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 58. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 59. Gilead Sciences, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 60. Incyte Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 61. Infinity Pharmaceuticals, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 62. Juno Therapeutics Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 63. MedImmune, LLC Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global Indolent Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of BI-836826
Table 3. Key Players of ALT-803
Table 4. Key Players of BMS-986016
Table 5. Key Players of CC-122
Table 6. Key Players of Others
Table 7. Global Indolent Lymphoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Indolent Lymphoma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Indolent Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Indolent Lymphoma Treatment Market Share by Region (2020-2025)
Table 11. Global Indolent Lymphoma Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Indolent Lymphoma Treatment Market Share by Region (2026-2031)
Table 13. Indolent Lymphoma Treatment Market Trends
Table 14. Indolent Lymphoma Treatment Market Drivers
Table 15. Indolent Lymphoma Treatment Market Challenges
Table 16. Indolent Lymphoma Treatment Market Restraints
Table 17. Global Indolent Lymphoma Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Indolent Lymphoma Treatment Market Share by Players (2020-2025)
Table 19. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2024)
Table 20. Ranking of Global Top Indolent Lymphoma Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Indolent Lymphoma Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Indolent Lymphoma Treatment, Headquarters and Area Served
Table 23. Global Key Players of Indolent Lymphoma Treatment, Product and Application
Table 24. Global Key Players of Indolent Lymphoma Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Indolent Lymphoma Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Indolent Lymphoma Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Indolent Lymphoma Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Indolent Lymphoma Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Indolent Lymphoma Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Indolent Lymphoma Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Indolent Lymphoma Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Indolent Lymphoma Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Indolent Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Indolent Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Altor BioScience Corporation Company Details
Table 50. Altor BioScience Corporation Business Overview
Table 51. Altor BioScience Corporation Indolent Lymphoma Treatment Product
Table 52. Altor BioScience Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 53. Altor BioScience Corporation Recent Development
Table 54. Amgen Inc. Company Details
Table 55. Amgen Inc. Business Overview
Table 56. Amgen Inc. Indolent Lymphoma Treatment Product
Table 57. Amgen Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 58. Amgen Inc. Recent Development
Table 59. Astellas Pharma Inc. Company Details
Table 60. Astellas Pharma Inc. Business Overview
Table 61. Astellas Pharma Inc. Indolent Lymphoma Treatment Product
Table 62. Astellas Pharma Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 63. Astellas Pharma Inc. Recent Development
Table 64. Bayer AG Company Details
Table 65. Bayer AG Business Overview
Table 66. Bayer AG Indolent Lymphoma Treatment Product
Table 67. Bayer AG Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 68. Bayer AG Recent Development
Table 69. Boehringer Ingelheim GmbH Company Details
Table 70. Boehringer Ingelheim GmbH Business Overview
Table 71. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product
Table 72. Boehringer Ingelheim GmbH Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 73. Boehringer Ingelheim GmbH Recent Development
Table 74. Bristol-Myers Squibb Company Company Details
Table 75. Bristol-Myers Squibb Company Business Overview
Table 76. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product
Table 77. Bristol-Myers Squibb Company Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 78. Bristol-Myers Squibb Company Recent Development
Table 79. Celgene Corporation Company Details
Table 80. Celgene Corporation Business Overview
Table 81. Celgene Corporation Indolent Lymphoma Treatment Product
Table 82. Celgene Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 83. Celgene Corporation Recent Development
Table 84. Eli Lilly and Company Company Details
Table 85. Eli Lilly and Company Business Overview
Table 86. Eli Lilly and Company Indolent Lymphoma Treatment Product
Table 87. Eli Lilly and Company Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 88. Eli Lilly and Company Recent Development
Table 89. F. Hoffmann-La Roche Ltd. Company Details
Table 90. F. Hoffmann-La Roche Ltd. Business Overview
Table 91. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product
Table 92. F. Hoffmann-La Roche Ltd. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 93. F. Hoffmann-La Roche Ltd. Recent Development
Table 94. Gilead Sciences, Inc. Company Details
Table 95. Gilead Sciences, Inc. Business Overview
Table 96. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product
Table 97. Gilead Sciences, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 98. Gilead Sciences, Inc. Recent Development
Table 99. Incyte Corporation Company Details
Table 100. Incyte Corporation Business Overview
Table 101. Incyte Corporation Indolent Lymphoma Treatment Product
Table 102. Incyte Corporation Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 103. Incyte Corporation Recent Development
Table 104. Infinity Pharmaceuticals, Inc. Company Details
Table 105. Infinity Pharmaceuticals, Inc. Business Overview
Table 106. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product
Table 107. Infinity Pharmaceuticals, Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 108. Infinity Pharmaceuticals, Inc. Recent Development
Table 109. Juno Therapeutics Inc. Company Details
Table 110. Juno Therapeutics Inc. Business Overview
Table 111. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product
Table 112. Juno Therapeutics Inc. Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 113. Juno Therapeutics Inc. Recent Development
Table 114. MedImmune, LLC Company Details
Table 115. MedImmune, LLC Business Overview
Table 116. MedImmune, LLC Indolent Lymphoma Treatment Product
Table 117. MedImmune, LLC Revenue in Indolent Lymphoma Treatment Business (2020-2025) & (US$ Million)
Table 118. MedImmune, LLC Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
Table 122. Authors List of This Report
List of Figures
Figure 1. Indolent Lymphoma Treatment Picture
Figure 2. Global Indolent Lymphoma Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Indolent Lymphoma Treatment Market Share by Type: 2024 VS 2031
Figure 4. BI-836826 Features
Figure 5. ALT-803 Features
Figure 6. BMS-986016 Features
Figure 7. CC-122 Features
Figure 8. Others Features
Figure 9. Global Indolent Lymphoma Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Indolent Lymphoma Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Indolent Lymphoma Treatment Report Years Considered
Figure 15. Global Indolent Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Indolent Lymphoma Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Indolent Lymphoma Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Indolent Lymphoma Treatment Market Share by Players in 2024
Figure 19. Global Top Indolent Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Lymphoma Treatment as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2024
Figure 21. North America Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 23. United States Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 27. Germany Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Indolent Lymphoma Treatment Market Share by Region (2020-2031)
Figure 35. China Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Indolent Lymphoma Treatment Market Share by Country (2020-2031)
Figure 47. Turkey Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Indolent Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Altor BioScience Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 51. Amgen Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 52. Astellas Pharma Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 53. Bayer AG Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 54. Boehringer Ingelheim GmbH Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 55. Bristol-Myers Squibb Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 56. Celgene Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 57. Eli Lilly and Company Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 58. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 59. Gilead Sciences, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 60. Incyte Corporation Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 61. Infinity Pharmaceuticals, Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 62. Juno Therapeutics Inc. Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 63. MedImmune, LLC Revenue Growth Rate in Indolent Lymphoma Treatment Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232